禮來(LLY.US)和諾和諾德(NVO.US)一路高歌 當前是否估值過高?
- 作者智通財經-
智通財經APP獲悉,禮來(LLY.US)和諾和諾德(NVO.US)股價近幾個月持續上漲,主要在於兩大巨頭各自生產的減肥或糖尿病藥物替扎帕肽(又名Zepbound)和司美格魯肽(又...
最新 | 高 | 低 | |||||
---|---|---|---|---|---|---|---|
201.1 | 201.1 | 196.3 | +4.9 | +2.52% | 2.67M | ||
989.8 | 992.2 | 985.6 | -2.4 | -0.24% | 173.71K | ||
1,058.0 | 1,069.5 | 1,058.0 | -12.0 | -1.12% | 200.03K | ||
903.3 | 919.0 | 901.1 | -9.6 | -1.05% | 2.11M | ||
11,430 | 11,885 | 11,405 | -270 | -2.31% | 25.65K | ||
435.4 | 438.0 | 430.7 | +3.1 | +0.72% | 578.62K | ||
11,040 | 11,450 | 11,020 | -260 | -2.30% | 4.6K | ||
2,041.0 | 2,063.0 | 2,027.0 | +15.0 | +0.74% | 71.03K | ||
221.3 | 222.3 | 211.7 | +7.0 | +3.27% | 1.03M | ||
191.6 | 198.1 | 191.4 | -7.6 | -3.82% | 2.55M | ||
335.0 | 337.4 | 329.0 | +4.0 | +1.21% | 295.18K | ||
142.0 | 143.2 | 141.7 | -0.5 | -0.35% | 710.53K | ||
850.0 | 856.4 | 838.2 | +9.0 | +1.07% | 244.41K | ||
130.2 | 131.8 | 128.9 | -1.5 | -1.10% | 366.68K | ||
544.5 | 549.5 | 543.5 | 0.0 | 0.00% | 90.74K | ||
1,169.5 | 1,176.0 | 1,160.0 | +5.5 | +0.47% | 133.74K | ||
2,672 | 2,688 | 2,604 | -6 | -0.22% | 57.94K | ||
130.90 | 132.10 | 130.60 | -0.70 | -0.53% | 353.73K | ||
419.50 | 435.10 | 415.50 | -12.90 | -2.98% | 674.9K |
智通財經APP獲悉,禮來(LLY.US)和諾和諾德(NVO.US)股價近幾個月持續上漲,主要在於兩大巨頭各自生產的減肥或糖尿病藥物替扎帕肽(又名Zepbound)和司美格魯肽(又...
智通財經APP獲悉,丹麥政府目前預計該國經濟今年將增長2.7%,幾乎是此前預期的兩倍。蓬勃發展的諾和諾德(NVO.US)加速了丹麥經濟增長。 丹麥經濟部上調了對2024年國內生產...
智通財經APP獲悉,中遠海運港口(01199)跌超3%,截至發稿,跌3.58%,報5.12港元,成交額7834.12萬港元。 消息面上,MSCI日前公佈2024年5月指數審議結果...